Respected Industry Veteran to Join Executive Leadership Team; Bringing Over 33 years of Experience in Global Capital Markets
MADISON HEIGHTS, MI / ACCESSWIRE / Apr 17, 2014 – Creative Edge Nutrition, Inc. (OTC Pink: FITX) (PINKSHEETS: FITX), CEN Biotech, announced today the appointment of John A. Germinario as Chairman of the Board of Directors effective immediately.
As a seasoned banker with over 33 years of experience in global capital markets, Mr. Germinario will be managing a variety of immediate tasks including regulatory compliance, risk management, corporate governance, potential mergers and acquisitions, assessing market strategy and spearheading financing activities.
“Our association with Mr. Germinario marks the first step in our relationship with Push Point Management Group and we are extremely pleased to have John as our Chairman. Our Board of Directors unanimously voted for his appointment given his expertise, leadership and results-driven track record,” commented Bill Chaaban, President & CEO. “His corporate ethics and entrepreneurial skills are valuable in establishing our long term vision and we are confident that his contributions will further enhance our shareholder value.”
Mr. Germinario currently serves as CEO of Global Securities Services Corporation an international strategic institution focused on designing and implementing Depositary Receipt Programs for publicly traded companies. Prior to joining CEN Biotech, Mr. Germinario was a global capital markets securities fraud examiner and worked with the U.S. Securities and Exchange Commission (SEC) and the Internal Revenue Service (IRS) Whistleblower to identify multiple levels of securities, bank and tax fraud, resulting in the collection of hundreds of millions of dollars in unpaid taxes by four major New York banks. Mr. Germinario continues to work with the SEC, Federal Bureau of Investigation (FBI) and the IRS on criminal investigations in an effort to provide a safe and secure share ownership experience for investors and shareholders.
About CEN Biotech
CEN Biotech, Inc. was established in 2013 as a partially owned subsidiary of Creative Edge Nutrition (OTC Pink: FITX) (PINKSHEETS: FITX) for the sole purpose of supplying the Canadian public with pharmaceutical-grade medical cannabis under the newly established Marihuana for Medical Purposes Regulations (MMPR). CEN Biotech Inc. has submitted a comprehensive application to become a licensed producer (LP) of dried marihuana for medicinal purposes and has received a ready-to-build approval from Health Canada.
About Creative Edge Nutrition, Inc.
Creative Edge Nutrition is a holding company and a Nutritional Supplement Company focused on developing innovative, high quality supplements. The company offers a broad spectrum of capsules, tablets, and powders, as well as science based products in the principal categories of weight management, nutrition challenges, energy and fitness. The Company manufactures under strict GMP guidelines at GMP Certified and/or FDA registered facilities. http://www.cenergynutrition.com and https://www.facebook.com/CenergyNutrition
About RXNB, Inc.
RXNB possesses proprietary, cutting-edge systems in the field of agriculture, applicable to medical marijuana. In particular, these technologies focus on Current Good Manufacturing Practices (cGMP) manufacturing and growing process of medicinal marijuana. cGMP refers to the Current Good Manufacturing Practice regulations enforced by the US Food and Drug Administration (FDA). cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities, which assures the identity, strength, quality, and purity of drug products. RXNB technologies will accelerate plant growth, allow perpetual grow cycles of about 35 days and protect plants from adulterants, which will yield greater harvests. RXNB has a pharmacy division, which dispenses prescription drugs direct to approximately 50,000 patients per month in the US. RXNB owns a distribution network, which supplies approximately 2,700 clinicians with tailored functional medicine across the US. It operates its own call center and owns software technologies in the field of tailored specialty drugs and batch record keeping in compliance with USP 797.
FOR INVESTOR RELATIONS
SOURCE: CEN Biotech, Inc.